These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 10669186

  • 1. Dofetilide: a class III-specific antiarrhythmic agent.
    Kalus JS, Mauro VF.
    Ann Pharmacother; 2000 Jan; 34(1):44-56. PubMed ID: 10669186
    [Abstract] [Full Text] [Related]

  • 2. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ, Markham A.
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [Abstract] [Full Text] [Related]

  • 3. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH, Decara JM.
    Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
    [Abstract] [Full Text] [Related]

  • 4. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H, Saliba W.
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
    [Abstract] [Full Text] [Related]

  • 5. Dofetilide: a new class III antiarrhythmic agent.
    Al-Dashti R, Sami M.
    Can J Cardiol; 2001 Jan; 17(1):63-7. PubMed ID: 11173316
    [Abstract] [Full Text] [Related]

  • 6. Dofetilide, a novel class III antiarrhythmic agent.
    Rasmussen HS, Allen MJ, Blackburn KJ, Butrous GS, Dalrymple HW.
    J Cardiovasc Pharmacol; 1992 Jan; 20 Suppl 2():S96-105. PubMed ID: 1279316
    [Abstract] [Full Text] [Related]

  • 7. Dofetilide, a new class III antiarrhythmic agent.
    Lenz TL, Hilleman DE.
    Pharmacotherapy; 2000 Jul; 20(7):776-86. PubMed ID: 10907968
    [Abstract] [Full Text] [Related]

  • 8. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter.
    Howard PA.
    Ann Pharmacother; 1999 Jan; 33(1):38-47. PubMed ID: 9972384
    [Abstract] [Full Text] [Related]

  • 9. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
    Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ.
    N Engl J Med; 1999 Sep 16; 341(12):857-65. PubMed ID: 10486417
    [Abstract] [Full Text] [Related]

  • 10. Dofetilide: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias.
    Shenasa F, Shenasa M.
    Card Electrophysiol Clin; 2016 Jun 16; 8(2):423-36. PubMed ID: 27261832
    [Abstract] [Full Text] [Related]

  • 11. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
    Falk RH, Pollak A, Singh SN, Friedrich T.
    J Am Coll Cardiol; 1997 Feb 16; 29(2):385-90. PubMed ID: 9014993
    [Abstract] [Full Text] [Related]

  • 12. Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.
    Banchs JE, Baquero GA, Nickolaus MJ, Wolbrette DL, Kelleman JJ, Samii S, Grando-Ting J, Penny-Peterson E, Davidson WR, Young SK, Naccarelli GV, Gonzalez MD.
    Congenit Heart Dis; 2014 Feb 16; 9(3):221-7. PubMed ID: 23947935
    [Abstract] [Full Text] [Related]

  • 13. Dofetilide: a new drug to control cardiac arrhythmia.
    Elming H, Brendorp B, Pedersen OD, Køber L, Torp-Petersen C.
    Expert Opin Pharmacother; 2003 Jun 16; 4(6):973-85. PubMed ID: 12783593
    [Abstract] [Full Text] [Related]

  • 14. A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?
    Wolbrette DL, Hussain S, Maraj I, Naccarelli GV.
    J Cardiovasc Pharmacol Ther; 2019 Jan 16; 24(1):3-10. PubMed ID: 29940780
    [Abstract] [Full Text] [Related]

  • 15. Practical approach to the use and monitoring of dofetilide therapy.
    Tran A, Vichiendilokkul A, Racine E, Milad A.
    Am J Health Syst Pharm; 2001 Nov 01; 58(21):2050-9. PubMed ID: 11715827
    [Abstract] [Full Text] [Related]

  • 16. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA, Banchs JE, Depalma S, Young SK, Penny-Peterson ED, Samii SM, Wolbrette DL, Naccarelli GV, Gonzalez MD.
    J Cardiovasc Electrophysiol; 2012 Mar 01; 23(3):296-301. PubMed ID: 21955243
    [Abstract] [Full Text] [Related]

  • 17. Dofetilide (Tikosyn): a new drug to control atrial fibrillation.
    Saliba WI.
    Cleve Clin J Med; 2001 Apr 01; 68(4):353-63. PubMed ID: 11326815
    [Abstract] [Full Text] [Related]

  • 18. Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.
    Jaiswal A, Goldbarg S.
    Indian Heart J; 2014 Apr 01; 66(6):640-8. PubMed ID: 25634399
    [Abstract] [Full Text] [Related]

  • 19. Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation.
    Torp-Pedersen C, Brendorp B, Køber L.
    Expert Opin Investig Drugs; 2000 Nov 01; 9(11):2695-704. PubMed ID: 11060831
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.
    Suttorp MJ, Polak PE, van 't Hof A, Rasmussen HS, Dunselman PH, Kingma JH.
    Am J Cardiol; 1992 Feb 01; 69(4):417-9. PubMed ID: 1734660
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.